Pharmacokinetics of superoxide dismutase in rats after oral administration

Biopharmaceutics and Drug Disposition

Volumn 17, Issue 2, 1996, Pages 165-174

  Regnault, C ^a   Soursac, M ^a   Roch Arveiller, M ^b   Postaire, E ^c   Hazebroucq, G ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Hôpital Cochin ^*  (France)

^c Pharm Centrale des Hôpitaux   (France)

Author keywords

Bioavailability; Ceramides; Liposomes; Oral administration; Pharmacokinetics; SOD

Indexed keywords

CERAMIDE; LIPOSOME; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; ENCAPSULATION; ENZYME ACTIVITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; DRUG EVALUATION, PRECLINICAL; INJECTIONS, SUBCUTANEOUS; LIPOSOMES; MALE; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE;

EID: 0029932860     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199603)17:2<165::AID-BDD945>3.0.CO;2-N     Document Type: Article

References (34)

1. G. Barja, Oxygen radicals, a failure or a success of evolution? Free Rad. Res. Commun., 18, 63-70 (1993).
2. J. C. Fulbert and M. J. Cals, Les radicaux libres en biologie clinique: origine, rôle pathogène et moyens de défense. Path. Biol., 40, 66-77 (1992).
3. J. Emerit, S. Pelletier, D. Tosoni-Verlignue and M. Mollet, Phase II trial of copper zinc superoxide dismutase (CuZnSOD) in treatment of Crohn's disease. Free Rad. Biol. Med., 7, 145-149 (1989).
4. M. K. Wilsmann, Ten years of clinical experience with SOD treatment of inflammatory disorders. In Superoxide and Superoxide Dismutase in Chemistry, Biology and Medicine, G. Rotilio (Ed.), Elsevier, Amsterdam, 1986, pp. 500-503.
5. K. M. Goebel and V. Storck, Effect of intra-articular orgotein versus corticosteroid on rheumatoid arthritis of the knee. Am. J. Med., 74, 124-128 (1983).
6. H. Marberger, W. Hurber, G. Bartsch, T. Schulte and P. Swoboda, Orgotein: a new anti-inflammatory metalloprotein drug. Evaluation of clinical efficacy and safety in inflammatory conditions of the urinary tract. Int. Urol. Nephrol., 6, 61-74 (1986).
7. M. Huhn-Edholm, E. Ostlinga and E. Fellenius, Superoxide dismutase enhances recovery following myocardial ischemia/reperfusion in vivo and in vitro. In Superoxide and Superoxide Dismutase in Chemistry, Biology and Medicine, G. Rotilio (Ed.), Elsevier, Amsterdam, 1986, pp. 591-593.
8. P. O. Sjoquist and S. L. Marklund, Endothelium bound extracellular superoxide dismutase type C reduces damage in reperfused ischaemic rat hearts. Cardiovasc. Res., 26, 347 (1992).
9. A. A. Youssefi, I. Emerit and J. Feingold, Oxyradical involvement in PUVA-induced skin reactions. Protection by local application of SOD. Eur. J. Dermatol., 4, 389-393 (1994).
10. T. Ranzi, L. Palmisano, L. Piodi, P. Velo and P. Bianchi, Orgotein suppositories in acute idiopathic proctitis. In Superoxide and Superoxide Dismutase in Chemistry, Biology and Medicine, G. Rotilio (Ed.), Elsevier, Amsterdam, 1986, pp. 548-550.
11. F. Edsmyr, Superoxide dismutase efficacy in ameliorating side effects of radiation therapy. Double-blind placebo-controlled trails in patients with bladder and prostate tumors. In Pathology of Oxygen, A. P. Autor (Ed.), Academic, New York, 1982, pp. 315-326.
12. H. Hiraishi, A. Terano and M. Razandi, Role of cellular superoxide dismutase against reactive oxygen metabolite injury in cultured bovine aortic endothelial cells. J. Biol. Chem., 267, 14812-14817 (1992).
13. N. Hatori, P. O. Sjoquist, S. L. Marklund and L. Ryden, Effect of recombinant human extracellular superoxide dismutase type C on myocardial infarct size in pigs. Free Rad. Biol. Med., 13, 221-226 (1992).
14. M. Inove, N. Watanabe and Y. Morino, Inhibition of oxygen toxicity by targeting superoxide dismutase to endothelial cell surface. FEBS Lett., 269, 89-92 (1990).
15. A. Conforti, M. Marrella, R. Milanino, U. Moretti, G. P. Velo, R. Largajolli, F. M. Veronese, E. Boccu and O. Schiavon, Anti-inflammatory properties of superoxide dismutase derivatives (SOD-PEG-3 and 18) in carrageenan pleurisy. In Superoxide and Superoxide Dismutase in Chemistry, Biology and Medicine, G. Rotilio (Ed.), Elsevier, Amsterdam, 1986, pp. 532-534.
16. R. Igarashi, J. Hoshino, M. Takenaga, S. Kawai, Y. Morizawa, A. Yasuda, M. Otani and Y. Mizushima, Lecithinization of superoxide dismutase potentiates its protective effect against forssman antiserum-induced elevation in guinea pig airway resistance. J. Pharmacol. Exp. Ther., 262, 1214-1219 (1992).
17. F. M. Veronese, E. Boccù, O. Schiavon, G. P. Velo, A. Conforti, L. Franco and R. Milanino, Anti-inflammatory and pharmacokinetic properties of superoxide dismutase derivatized with polyethylene glycol via active esters. J. Pharm. Pharmacol., 35, 757-758 (1983).
18. T. Oda, T. Akaite, T. Hamamoto, F. Suzuki, T. Hirano and H. Maeda, Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science, 244, 974-976 (1989).
19. J. F. Turrens, J. D. Crapo and B. A. Freeman, Protection against oxygen toxicity by intravenous injection of liposomal entrapped and superoxide dismutase. J. Clin. Invest., 73, 8795 (1984).
20. J. R. Lepock, L. D. Arnold, A. Petkau and K. Kelly, Interaction of superoxide dismutase with phospholipid liposomes: an uptake, spin label, and calorimetric study. Biochem. Biophys. Acta, 649, 45-57 (1981).
21. A. M. Michelson, K. Puget and P. Durosay, Studies of liposomal superoxide dismutase in rats. Mol. Physiol., 1, 85-96 (1981).
22. A. M. Michelson, K. Puget, B. Perdereau and C. Barbaroux, Scintigraphic studies on the localization of liposomal superoxide dismutase injected into rabbits. Mol. Physiol., 1, 71-84 (1981).
23. B. Freeman, S. L. Young and J. D. Crapo, Liposome mediated augmentation of superoxide dismutase in endothelial cells prevents oxygen injury. J. Biol. Chem., 258, 12 534-12 542 (1983).
24. S. Delanian, F. Baillet, J. Huart, J. L. Lefaix, C. Maulard and M. Housset, Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother. Oncol., 32, 12-20 (1994).
25. A. M. Michelson and K. Puget, Cell penetration by exogenous superoxide dismutase. Acta Physiol. Scand., 492 (suppl.), 67-80 (1980).
26. H. Noda, T. Ogasawara, T. Lida, H. Yamakawa, H. Michishita, T. Mitani, M. Kurono and K. Yagi, Pharmacodynamics and tumoricidal effect of adriamycin entrapped in ceramide sulfate-containing liposomes. Biol. Pharm. Bull., 17, 1246-1250 (1994).
27. J. M. McCord and I. Fridovich, Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem., 244, 6049-6055 (1969).
28. C. Regnault, C. Beaoist, H. Fessi, M. Roch-Arveiller and G. Hazebroucq, Preparation of superoxide dismutase entrapped in ceramide-containing liposomes for oral administration. Int. J. Pharm, in press.
29. E. Argese, R. Girotto and E. Orsega, Comparative kinetic study between native and chemically modified Cu, Zn superoxide dismutases. Biochem. J., 292, 451-455 (1993).
30. F. M. Veronese, P. Caliceti, A. Pastorino, O. Schiavon and L. Sartore, Preparation, physico-chemical and pharmacokinetic characterization of monomethoxypoly (ethylene glycol)-derivated superoxide dismutase. J. Controlled Rel., 10, 145-154 (1989).
31. S. Zidenberg-Cherr, S. Keen, C. L. Lonnerdal and L. S. Hurley, Dietary superoxide dismutase does not affect tissue levels. Am. J. Clin. Nutr., 37, 5-7 (1983).
32. S. N. Giri and H. P. Misra, Fate of superoxide dismutase in mice following oral route of administration. Mol. Biol., 62, 285-289 (1984).
33. J. Ghislain, C. A. Lingwood and E. N. Fish, Evidence for glycosphingolipid modification of the Type 1 IFN receptor. J. Immunol., 153, 3655-3663 (1994).
34. A. H. Merrill, Cell regulation by sphingosine and more complex sphingolipids. J. Bioenerg. Biomembr., 13, 83-87 (1991).